All News

The RHeumNow Podcast is up! Stop These COVID Mistakes(12.11.20). Loss of life in RA, Predicting Difficult RA, New drugs, COVID vaccine recommendations & what to tell your patients during the pandemic. Watch here>> https://t.co/w1g6ePwYPB or listen here>> https://t.co/Qu39ZLcgkm

Links:

Dr. John Cush RheumNow ( View Tweet)

RN.podcast.resized.jpg

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
tick.jpg

New Lyme Disease Guidelines

d Jack Cush, MD

2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR).

Read Article
covid.corona

Rheumatic Disease and COVID-19: Who Is at Risk?

d MedPage Today

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

Read Article
ACR has released 2 free powerpoint slide decks featuring select RA and SLE abstracts from #ACR20 (a 3rd late-breaking slide deck is yet to come!). Download here>> https://t.co/CiNH0xfs7J

Links:

Dr. John Cush RheumNow ( View Tweet)

Taiwanese claims data on new RA (2003‐2016) shows decreasing incidence over time. After RA Dx the life expectancy was 26.3 yrs; lifetime cost US$ 72,953. On avg RA pts live 4.97 years less (historically this was 8-11yrs); has biologic era improved this? https://t.co/gHbZx1bw0A

Links:

Dr. John Cush RheumNow ( View Tweet)

Hepatitis B, RA and Drug Risk with Drs. Stanley Cohen and Jack Cush #ACR20 https://t.co/jOzAkLzNEc https://t.co/lPM8bbHDr7

Links:

Dr. John Cush RheumNow ( View Tweet)
1st refractory to DMARD can be bad omen. RA Study showed 41/402 (10%) were multi-DMARD refractory (MR) and 18% achieved remission/LDAS. DMARD MR predicted by erosions, younger age, high baseline DAS28, delta-DAS < 1.2 1st 6 mos (OR 11.12) https://t.co/KxdK97uuSI

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @KDAO2011 : Big wins for #pedirheum! #FDA had approved for JIA;2 y.o: 9/29 golimumab iV for JIA/PsA 9/25 tofacitinib (weight based dosing) for polyarticular JIA (tofacitinib dosing for JIA: 10 kg-20kg: 3.2 mg bid, for 20-40 kg 4 mg bid, for 40 kg 5 mg bid)

Dr. John Cush RheumNow ( View Tweet)

ABCs of RA: Panel Discussion with Dr. Jonathan Kay #acr20 https://t.co/9HTTyPjCBV https://t.co/uDtS2EsMng

Links:

Dr. John Cush RheumNow ( View Tweet)
steroids.prednisone.pills_.jpg

Mortality in Low Dose Prednisone

d Eric Dein, MD

Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.

Read Article
#BestACR20Tweets RT @RichardPAConway : Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/TR9IS9hUgu
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets "RT @drdavidliew : Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/x7DLzZcn9o https://t.co/OmpTAorA13

Links:

Dr. John Cush RheumNow ( View Tweet)
podcast logo

RheumNow Podcast – Back Talk Listener Questions (12.04.20)

d Jack Cush, MD

Dr Jack Cush takes questions from RheumNow listeners

Read Article
#BestACR20Tweets RT @MeralElRamahiMD : Wonder if you can predict which pts you can taper off bDMARDs? Abst#1538 from Denmark showed that a neg IgM-RF (OR 0.26); low Doppler serum score for 24 jts predicted discontinuation of bDMARDs at 2yr f/u in RA pts w/ DAS28-CRP&lt;2.6. https://t.co/6hv5M1CQwT
Dr. John Cush RheumNow ( View Tweet)
Coal Miners and RA: Dr Janet Pope ( @Janetbirdope) reviews abstract #1462 presented at #ACR20. https://t.co/frZ3uYNsuA https://t.co/nFHmzYA8KS

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U

Links:

Dr. John Cush RheumNow ( View Tweet)
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20 https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Use MTX, starting oral but remember MTX tricks to maximize success. Folic acid, split dosing, SubQ all keys per Dr. O'Dell to maximize @RheumNow. https://t.co/OEAGi0bSZH https://t.co/aHsHF1Vm4l

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.